Literature DB >> 31550968

microRNA-221 restricts human cytomegalovirus replication via promoting type I IFN production by targeting SOCS1/NF-κB pathway.

Beizhan Yan1, Huimin Ma, Shuting Jiang, Jingli Shi, Ziyi Yang, Weiyan Zhu, Cunquan Kong, Lin Chen, Hui Yan, Cuixia Ma.   

Abstract

HCMV is a common pathogen for human with relatively high prevalence, which could be life-threatened in immunodeficient patients and lead to significant birth defects in newborns. In this study, we firstly report that HCMV infection significantly enhances the expression of microRNA-221 (miR-221) in Neural Precursor Cells (NPCs). We found that miR-221 directly targets at the 3'-UTR of suppressor of cytokine signaling 1 (SOCS1) and suppresses SOCS1 expression at the both mRNA and protein levels. MiR-221 overexpression restrained HCMV replication by promoting type I interferon (IFN) and interferon stimulating genes (ISGs) production, whereas reintroduction of SOCS1 abrogated the miR-221-induced effects on HCMV replication. Importantly, miR-221 positively regulated the phosphorylation and activation of NF-κB by suppressing SOCS1. What's more, miR-221 agomir alleviated MCMV-induced tissue injury by promoting type I IFN antiviral activities in vivo. Thus, miR-221 modulates the infection and replication of HCMV as an intrinsic antiviral factor, and could be developed as a treatment target for anti-HCMV treatment.

Entities:  

Keywords:  HCMV; Mir-221; SOCS1/NF-κB signaling; type I IFN

Year:  2019        PMID: 31550968      PMCID: PMC6816349          DOI: 10.1080/15384101.2019.1667706

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  31 in total

Review 1.  Regulation of TLR signaling and inflammation by SOCS family proteins.

Authors:  Akihiko Yoshimura; Hiroyuki Mori Masanobu Ohishi; Daisuke Aki; Toshikatsu Hanada
Journal:  J Leukoc Biol       Date:  2004-01-14       Impact factor: 4.962

Review 2.  Biological functions of microRNAs: a review.

Authors:  Yong Huang; Xing Jia Shen; Quan Zou; Sheng Peng Wang; Shun Ming Tang; Guo Zheng Zhang
Journal:  J Physiol Biochem       Date:  2010-10-28       Impact factor: 4.158

3.  Inducible microRNA-155 feedback promotes type I IFN signaling in antiviral innate immunity by targeting suppressor of cytokine signaling 1.

Authors:  Pin Wang; Jin Hou; Li Lin; Chunmei Wang; Xingguang Liu; Dong Li; Feng Ma; Zhugang Wang; Xuetao Cao
Journal:  J Immunol       Date:  2010-10-11       Impact factor: 5.422

Review 4.  30 Years of NF-κB: A Blossoming of Relevance to Human Pathobiology.

Authors:  Qian Zhang; Michael J Lenardo; David Baltimore
Journal:  Cell       Date:  2017-01-12       Impact factor: 41.582

5.  MicroRNA-182 inhibits HCMV replication through activation of type I IFN response by targeting FOXO3 in neural cells.

Authors:  Xia He; Junfang Teng; Can Cui; Dongrui Li; Lijun Wen
Journal:  Exp Cell Res       Date:  2018-05-21       Impact factor: 3.905

6.  The life cycle and pathogenesis of human cytomegalovirus infection: lessons from proteomics.

Authors:  Pierre M Jean Beltran; Ileana M Cristea
Journal:  Expert Rev Proteomics       Date:  2014-10-18       Impact factor: 3.940

7.  SOCS1, a Negative Regulator of Cytokine Signals and TLR Responses, in Human Liver Diseases.

Authors:  Minoru Fujimoto; Tetsuji Naka
Journal:  Gastroenterol Res Pract       Date:  2010-09-02       Impact factor: 2.260

Review 8.  Negative regulation of cytokine signaling and immune responses by SOCS proteins.

Authors:  Akihiko Yoshimura; Hitomi Nishinakamura; Yumiko Matsumura; Toshikatsu Hanada
Journal:  Arthritis Res Ther       Date:  2005-03-30       Impact factor: 5.156

9.  Cell fate in antiviral response arises in the crosstalk of IRF, NF-κB and JAK/STAT pathways.

Authors:  Maciej Czerkies; Zbigniew Korwek; Wiktor Prus; Marek Kochańczyk; Joanna Jaruszewicz-Błońska; Karolina Tudelska; Sławomir Błoński; Marek Kimmel; Allan R Brasier; Tomasz Lipniacki
Journal:  Nat Commun       Date:  2018-02-05       Impact factor: 14.919

10.  miR-215 Enhances HCV Replication by Targeting TRIM22 and Inactivating NF-κB Signaling.

Authors:  Hui Tian; Zhenkun He
Journal:  Yonsei Med J       Date:  2018-06       Impact factor: 3.052

View more
  6 in total

Review 1.  Human Cytomegalovirus Induced Aberrant Expression of Non-coding RNAs.

Authors:  Zhongjie Yu; Jing Wang; Fulong Nan; Wenyi Shi; Xianjuan Zhang; Shasha Jiang; Bin Wang
Journal:  Front Microbiol       Date:  2022-06-13       Impact factor: 6.064

2.  Suppressor of cytokine signaling 1 inhibits the maturation of dendritic cells involving the nuclear factor kappa B signaling pathway in the glioma microenvironment.

Authors:  M He; X Chen; M Luo; L Ouyang; L Xie; Z Huang; A Liu
Journal:  Clin Exp Immunol       Date:  2020-06-30       Impact factor: 4.330

3.  Downregulation of microRNA‑221 facilitates H1N1 influenza A virus replication through suppression of type‑IFN response by targeting the SOCS1/NF‑κB pathway.

Authors:  Nali Zhang; Yuan Ma; Yuheng Tian; Yafei Zhou; Yuhua Tang; Shaobo Hu
Journal:  Mol Med Rep       Date:  2021-05-06       Impact factor: 2.952

4.  Junin Virus Activates p38 MAPK and HSP27 Upon Entry.

Authors:  Collin J Fitzpatrick; Rajini R Mudhasani; Louis A Altamura; Catherine E Campbell; Julie P Tran; Brett F Beitzel; Aarthi Narayanan; Cynthia L de la Fuente; Kylene Kehn-Hall; Jeffrey M Smith; Connie S Schmaljohn; Aura R Garrison
Journal:  Front Cell Infect Microbiol       Date:  2022-04-07       Impact factor: 6.073

Review 5.  The Emerging Role of Non-Coding RNAs in the Regulation of Virus Replication and Resultant Cellular Pathologies.

Authors:  Soudeh Ghafouri-Fard; Bashdar Mahmud Hussen; Hazha Hadayat Jamal; Mohammad Taheri; Guive Sharifi
Journal:  Int J Mol Sci       Date:  2022-01-13       Impact factor: 5.923

Review 6.  The potential use of microRNAs as a therapeutic strategy for SARS-CoV-2 infection.

Authors:  Jiulue Hu; Jelena Stojanović; Saman Yasamineh; Pooneh Yasamineh; Sathish Kumar Karuppannan; Mohammed Junaid Hussain Dowlath; Hamed Serati-Nouri
Journal:  Arch Virol       Date:  2021-07-19       Impact factor: 2.574

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.